Ask AI
ProCE Banner Activity

The Muscarinic Revolution: A Novel Treatment Paradigm for Schizophrenia

Clinical Thought

Read this commentary sharing practical strategies and clinical insights into the evolving treatment landscape of schizophrenia, with a focus on presynaptic mechanisms and the emergence of xanomeline/trospium. By examining the neurodevelopmental origins of dopamine dysregulation and the unique pharmacology of muscarinic modulation, healthcare professionals can better individualize care for patients with persistent symptoms and cognitive deficits.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb. 

Bristol Myers Squibb

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the mechanisms of action and pharmacokinetic profiles of novel and emerging therapeutic agents for schizophrenia, extending beyond traditional antidopaminergic antipsychotics

  • Compare the efficacy and safety data of novel and emerging agents in the treatment of schizophrenia

  • Describe the potential of novel antipsychotic therapies to address unmet needs and transform clinical practice in schizophrenia management

Disclosure

Primary Author

Jonathan M. Meyer, MD, DLFAPA: consultant/advisor/speaker: 4MTx, AbbVie, Alkermes, Autobahn, Axsome, Bristol Myers Squibb, Intra-Cellular/Johnson & Johnson, Luye, Neurocrine, Teva.